Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

The tissue factor pathway inhibitor (TFPI) antagonist, given as a subcutaneous injection, has been cleared to prevent or reduce bleeding episodes in patients aged 12 years and older with ...